PBS removes hep B prescribing barrier — GPs can initiate from today

What just happened

From today — 1 September 2026 — GPs and authorised nurse practitioners no longer need Section 100 prescriber accreditation to initiate and manage PBS-subsidised hepatitis B treatment.

That sentence is bureaucratic. What it means, practically: for the approximately 219,800 Australians living with chronic hepatitis B, of whom only one in four was receiving treatment under the old system, care has moved considerably closer to home.

The change affects the PBS Highly Specialised Drugs program. Previously, prescribing hepatitis B medicines required mandatory specialist accreditation — a credentialling hurdle that meant, in practice, that over 75% of hepatitis B treatment was delivered by specialists at hospital clinics. In many parts of Australia, those clinics had waitlists exceeding two years.

Dr Sara Whitburn, commenting on the change for RACGP media, put it plainly: the old requirement was “an administrative and logistical barrier that at times may have delayed treatment initiation.” The Department of Health framed the change as one that “better aligns legislative requirements with the contemporary clinical landscape.”

One important clarification: this change does not remove hospital-based pathways for hepatitis C. PBS hepatitis C medicines remain hospital-based for initiation. The accreditation removal applies to hepatitis B treatment specifically.

---

The both-and

Why this matters beyond administration

Chronic hepatitis B is not a mild condition. Untreated, it carries long-term risk of cirrhosis and hepatocellular carcinoma — two serious, life-altering complications that are substantially preventable with effective antiviral treatment. The treatment landscape has improved markedly in the past decade; the barrier has not been the medicine, it has been the system.

The burden falls disproportionately on specific communities — people born in regions where hepatitis B is endemic (Southeast Asia, sub-Saharan Africa, Pacific Island nations) and their Australian-born children, as well as people experiencing social disadvantage who may find specialist clinic systems harder to navigate. These are also the communities most likely to face the greatest access barriers under a specialist-first model.

A two-year hospital waitlist in a metropolitan centre does not serve someone in rural New South Wales or regional Queensland. Nor does it serve someone for whom a specialist referral — with its complexity, cost, and delay — is itself the barrier to care. The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine welcomed the change precisely on these grounds, noting it would bring care closer to home and reduce pressure on specialist services already stretched well beyond capacity.

That logic is sound. When a medication is safe, effective, and already managed long-term by GPs in terms of monitoring and follow-up, restricting initiation to accredited specialists is a barrier to access, not a quality safeguard.

What the change does not resolve

GPs still need to meet clinical requirements before initiating PBS hepatitis B medicines: evidence of chronic infection, prior treatment history where relevant, and documentation of cirrhotic status. This is genuine clinical judgment, not a rubber stamp.

Some GPs may feel underprepared for hepatitis B initiation — the accreditation pathway, while burdensome, did create a structured educational route. The information is available through existing resources: ASHM clinical guidelines, eTG Complete, and the RACGP’s hepatitis management resources. But GPs who have not previously managed hepatitis B directly will need to build that clinical confidence deliberately.

This is also a partial step. Hepatitis C treatment — for which direct-acting antivirals have been genuinely transformative since PBS listing in 2016 — remains hospital-based. There is a reasonable case for extending GP-initiation authority to hepatitis C in due course, particularly for people who have achieved sustained virological response and need follow-up rather than de novo initiation. That is a separate and overdue conversation.

---

My two cents

One in four people with chronic hepatitis B receiving treatment is a system problem, not a patient problem. Hepatitis B is largely asymptomatic for years; people do not present with urgency they can feel. When the treatment pathway then requires specialist accreditation, a referral, a waitlist exceeding two years, and a system concentrated in metropolitan centres — the gap between diagnosis and treatment is not surprising. It is structural.

This is one of those policy changes where the mechanism is unglamorous and the effect is real. A GP in a regional town who now holds the prescribing authority they previously lacked is a material change in care access for their patients. That patient who has been on a specialist waitlist for eighteen months may now be able to start treatment at their next appointment.

If you have chronic hepatitis B and have not been receiving treatment — whether because of access, cost, or a waitlist — this change is worth raising at your next GP appointment.

Verdict: yes — a concrete access gain, effective today, for a condition that responds well to treatment when people can actually reach it.

---

Sources cited

1. Training requirement scrapped for GPs prescribing hepatitis — newsGP, 1 September 2026. https://www1.racgp.org.au/newsgp/clinical/training-requirement-scrapped-for-gps-hepatitis-pr
2. PBS drops hep B accreditation — Medical Republic, 1 September 2026. https://www.medicalrepublic.com.au/pbs-drops-hep-c-accreditation/128652